Survival rates were 89.2% for 1 year, 63.9% for 3 years and 53.0% for 5 years in patients with OPG-reduced CRC, and 100.0% for 1 year, 81.4% for 3 years and 76.5% for 5 years in patients with OPG-positive CRC. Here, TNFRSF11B is linked to colorectal carcinoma.